Prophylactic Ketamine: Current Knowledge and Future Directions.
Cardona-Acosta AM, Parise LF, Bolaños-Guzmán CA, Parise EM.
Biol Psychiatry · review; journal article · DOI 10.1016/j.biopsych.2025.03.015 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för (2S,6S)-6-hydroxynorketamine. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
11 hitsMapping Fear-Related Neural Activity and Circuitry Changes Following Prophylactic Administration of (R,S)-Ketamine and (2S,6S)-Hydroxynorketamine.
Li M, Cheng L.
Neurosci Bull · research-article; journal article · DOI 10.1007/s12264-025-01362-yProphylactic (R,S)-Ketamine and (2S,6S)-Hydroxynorketamine Decrease Fear Expression by Differentially Modulating Fear Neural Ensembles.
Mastrodonato A, Jin M, Kee N, Lanio M, Tapia J, Quintana L, Muñoz Zamora A, Deng SX, Xu X, Landry DW, Denny CA.
Biol Psychiatry · research-article; journal article · DOI 10.1016/j.biopsych.2024.09.024Study on the antidepressant activity of (2R,6R; 2S,6S)-Hydroxynorketamine (HNK) and its derivatives.
Zang D, Yang X, Wang H, Li Z, Ma Y, Liu J, Mei X, Li S, Feng J, Shi X, Tan Z.
Clinics (Sao Paulo) · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.clinsp.2024.100435Sustained antidepressant effects of ketamine metabolite involve GABAergic inhibition-mediated molecular dynamics in aPVT glutamatergic neurons.
Kawatake-Kuno A, Li H, Inaba H, Hikosaka M, Ishimori E, Ueki T, Garkun Y, Morishita H, Narumiya S, Oishi N, Ohtsuki G, Murai T, Uchida S.
Neuron · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.neuron.2024.01.023Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.
Yamagishi A, Ikekubo Y, Mishina M, Ikeda K, Ide S.
J Pharmacol Sci · journal article · DOI 10.1016/j.jphs.2024.01.008Chiral LC-MS/MS method for the simultaneous determination of (R,S)-ketamine, (R,S)-norketamine, and (2R,6R;2S,6S)-hydroxynorketamine in mouse plasma and brain.
Toki H, Yamaguchi JI, Mizuno-Yasuhira A, Endo H.
J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2022.115168Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, Cooper TB, Shah A, Brachman RA, Mendez-David I, David DJ, Gardier AM, Landry DW, Denny CA.
Neuropsychopharmacology · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41386-020-0714-z(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Yokoyama R, Higuchi M, Tanabe W, Tsukada S, Naito M, Yamaguchi T, Chen L, Kasai A, Seiriki K, Nakazawa T, Nakagawa S, Hashimoto K, Hashimoto H, Ago Y.
Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2020.172876The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.
Moaddel R, Sanghvi M, Dossou KS, Ramamoorthy A, Green C, Bupp J, Swezey R, O'Loughlin K, Wainer IW.
Pharmacol Res Perspect · research-article; journal article · DOI 10.1002/prp2.157(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.
Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O'Loughlin K, Torjman MC, Bernier M, Wainer IW.
Anesthesiology · research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/aln.0000000000000285